Literature DB >> 31515313

Biosimilars versus biologics for inflammatory conditions.

Danielle Perry1, Joey Ton1, Michael R Kolber2.   

Abstract

Year:  2019        PMID： 31515313      PMCID： PMC6741793     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  12 in total

1.  A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.

Authors:  Sang-Cheol Bae; Jinseok Kim; Jung-Yoon Choe; Won Park; Sang-Heon Lee; Yong-Beom Park; Seung-Cheol Shim; Shin-Seok Lee; Yoon-Kyoung Sung; Chan-Bum Choi; So-Ra Lee; HanYu Park; Yongho Ahn
Journal:  Ann Rheum Dis       Date:  2016-02-23       Impact factor: 19.103

2.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

3.  Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hisashi Yamanaka; Yoshiya Tanaka; Takeo Sakurai; Kazuyoshi Saito; Hideo Ohtsubo; Sang Joon Lee; Yoshihiro Nambu
Journal:  Mod Rheumatol       Date:  2015-04-02       Impact factor: 3.023

4.  A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Authors:  Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieskawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Jasmine Choi; Young Hee Rho; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2015-08-28       Impact factor: 19.103

5.  A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.

Authors:  Josef S Smolen; Stanley B Cohen; Hans-Peter Tony; Morton Scheinberg; Alan Kivitz; Andra Balanescu; Juan Gomez-Reino; Liyi Cen; Peijuan Zhu; Tamas Shisha
Journal:  Ann Rheum Dis       Date:  2017-06-21       Impact factor: 19.103

6.  Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

Authors:  Josef S Smolen; Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieskawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Jasmine Choi; Young Hee Rho
Journal:  Rheumatology (Oxford)       Date:  2017-10-01       Impact factor: 7.580

7.  Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

Authors:  Josef S Smolen; Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieslawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Younju Lee; Young Hee Rho
Journal:  Ann Rheum Dis       Date:  2017-10-17       Impact factor: 19.103

8.  Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

Authors:  Stanley Cohen; Mark C Genovese; Ernest Choy; Fernando Perez-Ruiz; Alan Matsumoto; Karel Pavelka; Jose L Pablos; Warren Rizzo; Pawel Hrycaj; Nan Zhang; William Shergy; Primal Kaur
Journal:  Ann Rheum Dis       Date:  2017-06-05       Impact factor: 19.103

9.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

10.  A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

Authors:  Paul Emery; Jiří Vencovský; Anna Sylwestrzak; Piotr Leszczyński; Wieslawa Porawska; Asta Baranauskaite; Vira Tseluyko; Vyacheslav M Zhdan; Barbara Stasiuk; Roma Milasiene; Aaron Alejandro Barrera Rodriguez; Soo Yeon Cheong; Jeehoon Ghil
Journal:  Ann Rheum Dis       Date:  2015-07-06       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.